Clinical Research Directory

Inclusion Criteria: 1. ≥19 years of age 2. Patient agreed to participate in the study and signed a written informed consent form 3. Type 2 diabetes (ADA criteria) 4. HbA1c≥7.0% and \<10.0% in patients receiving monotherapy, dual-combination therapy, or triple-combination therapy (when the submaximal dose was administered) with oral antidiabetic drugs (OADs) 5. Any of the following: A. Patients who one or more of the following conditions 1. Coronary artery disease 2. Atherosclerotic ischemic stroke, transient ischemic attack, carotid artery disease, peripheral artery disease, abdominal aortic aneurysm 3. Prevalence of diabetes ≥10 years 4. Left ventricular hypertrophy 5. Albuminuria 6. Chronic kidney disease (eGFR\<60mL/min/1.73m²) 7. Diabetic Retinopathy 8. Diabetic neuropathy or B. Patients who have two or more of the following cardiovascular risk factors (1) Family history of early-onset ASCVD (first-degree relatives with disease before age 55 for men and before age 65 for women) (2) Hypertension (on medication or with SBP≥140 mm Hg or DBP≥90 mm Hg) (3) Low HDL cholesterol concentration (\<40 mg/dL) (4) Current smoker (5) Obese (BMI≥25 kg/m²) Exclusion Criteria: 1. Type 1 diabetes 2. Estimated GFR\<45 ml/min/1.73m² 3. AST or ALT greater than 3 times the normal upper limit 4. Symptomatic heart failure (NYHA Class III or IV) 5. History of hospitalization for acute cardiovascular events within 3 months prior to the date of consent 6. Currently in active treatment for malignancy 7. Contraindications for each assigned drug, as applicable 8. Pregnant and nursing women 9. If the investigator determines that assignment to the standard glycemic control arm raises ethical concerns